Stock Financial Ratios, Dividends, Split History

BIVV / Bioverativ Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price104.98
Volume792,900.00
Market Cap ($M)11,390.33
Enterprise Value ($M)10,953.83
Book Value ($M)897.60
Book Value / Share8.27
Price / Book12.69
NCAV ($M)57.60
NCAV / Share0.53
Price / NCAV197.75
Income Statement (mra) ($M)
Revenue1,168.50
EBITDA447.20
Net Income355.60
Balance Sheet (mrq) ($M)
Cash & Equivalents436.50
Cash / Share4.02
Assets1,618.30
Liabilities720.70
Quick Ratio1.89
Current Ratio2.00
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding108,500,000
Preferred Stock Shares Outstanding0
Common Stock Shares Outstanding108,203,439
Common Shares Outstanding108,223,644
Weighted Average Number Diluted Shares Outstanding Adjustment400,000
Weighted Average Number Of Shares Outstanding Basic108,100,000
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.40
Return on Assets (ROA)
Return on Equity (ROE)
Identifiers and Descriptors
CUSIP09075E100
Central Index Key (CIK)1681689
Industry Groups

Split History

Stock splits are used by Bioverativ Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Peers -

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

11h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

Related News Stories

Biogen: Down Too Far, Too Fast?

57m seekingalpha
The article reviews reasons that downside risk may be fundamentally manageable (not zero, though), and why it may be attractive technically, as well. (108-0)

Sanofi to Divest European Generic Unit, Streamline Business

2018-04-19 zacks
Sanofi (SNY - Free Report) has entered into exclusive negotiations with private equity firm, Advent International to sell its European generic unit, Zentiva. Advent has offered a binding and fully financed offer to buy Zentiva for $2.4 billion (1.9 billion euros). (49-0)

Advent is said to near deal to acquire Sanofi Generics unit

2018-04-16 livemint
London:Advent International Corp. is close to acquiring Sanofi’s European generics division in a deal valued at about 2 billion euros ($2.5 billion) including debt, people with knowledge of the matter said. (45-0)

Alexion (ALXN) to Acquire Wilson Therapeutics for $855M

2018-04-12 zacks
Alexion Pharmaceuticals, Inc. (ALXN - Free Report) is the latest company to join the ongoing acquisitions spree in the biotech sector. The company recently announced that it will acquire Sweden-based Wilson Therapeutics. (152-0)

European Buyers Go Shopping for U.S. Companies - WSJ

2018-04-07 wsj
European executives are targeting U.S. companies as a brighter economic landscape at home and abroad boosts buyer confidence. (54-0)

CUSIP: 09075E100